Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTU NASDAQ:INKT NASDAQ:MREO NASDAQ:RKTO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$2.02-2.9%$2.47$1.58▼$11.99$48.33M0.92119,104 shs102,432 shsINKTMiNK Therapeutics$12.20$11.09$6.80▼$76.00$60.78M0.4736,262 shs64,005 shsMREOMereo BioPharma Group$0.34-0.3%$0.30$0.20▼$3.05$55.07M0.245.94 million shs3.87 million shsRKTORocket One Inc. Common Stock$1.70+25.0%$0.76$0.49▼$2.12$32.52M0.579.09 million shs93.91 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics-2.88%-15.13%-29.86%-45.99%-81.28%INKTMiNK Therapeutics0.00%+12.24%+3.30%+11.42%+71.83%MREOMereo BioPharma Group-0.29%+23.61%+24.46%-7.18%-84.29%RKTORocket One Inc. Common Stock-2.47%+146.38%+137.93%+68.32%+100.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$2.02-2.9%$2.47$1.58▼$11.99$48.33M0.92119,104 shs102,432 shsINKTMiNK Therapeutics$12.20$11.09$6.80▼$76.00$60.78M0.4736,262 shs64,005 shsMREOMereo BioPharma Group$0.34-0.3%$0.30$0.20▼$3.05$55.07M0.245.94 million shs3.87 million shsRKTORocket One Inc. Common Stock$1.70+25.0%$0.76$0.49▼$2.12$32.52M0.579.09 million shs93.91 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics-2.88%-15.13%-29.86%-45.99%-81.28%INKTMiNK Therapeutics0.00%+12.24%+3.30%+11.42%+71.83%MREOMereo BioPharma Group-0.29%+23.61%+24.46%-7.18%-84.29%RKTORocket One Inc. Common Stock-2.47%+146.38%+137.93%+68.32%+100.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 2.33Hold$17.50766.34% UpsideINKTMiNK Therapeutics 2.40Hold$35.00186.89% UpsideMREOMereo BioPharma Group 2.13Hold$3.25844.77% UpsideRKTORocket One Inc. Common Stock 2.00Hold$5.00194.12% UpsideCurrent Analyst Ratings BreakdownLatest RKTO, MREO, INKT, and ACTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/18/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.005/12/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026MREOMereo BioPharma Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/12/2026MREOMereo BioPharma Group BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.004/24/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026RKTORocket One Inc. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/22/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.004/13/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $15.004/1/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.00(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/A$0.16 per shareN/AINKTMiNK TherapeuticsN/AN/AN/AN/A($2.55) per shareN/AMREOMereo BioPharma Group$500K109.82N/AN/A$0.21 per share1.64RKTORocket One Inc. Common StockN/AN/AN/AN/A$0.22 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$22.23M-$0.97N/AN/AN/AN/A-430.93%-180.86%N/AINKTMiNK Therapeutics-$12.49M-$2.84N/AN/AN/AN/AN/A-118.57%8/13/2026 (Estimated)MREOMereo BioPharma Group-$41.88M-$0.05N/A34.40N/AN/A-81.28%-70.45%8/11/2026 (Estimated)RKTORocket One Inc. Common Stock-$12.47M-$0.80N/AN/AN/AN/A-165.25%-143.61%6/3/2026 (Estimated)Latest RKTO, MREO, INKT, and ACTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/ARKTORocket One Inc. Common Stock-$0.1378N/AN/AN/AN/AN/A5/15/2026Q1 2026INKTMiNK Therapeutics-$0.77-$0.57+$0.20-$0.57N/AN/A5/15/2026Q1 2026RKTORocket One Inc. Common Stock-$0.1378-$0.17-$0.0322-$0.17N/AN/A5/14/2026Q1 2026ACTUActuate Therapeutics-$0.23-$0.24-$0.01-$0.24N/AN/A5/12/2026Q1 2026MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.05$11.67 millionN/A3/27/2026Q4 2025RKTORocket One Inc. Common Stock-$0.1031-$0.16-$0.0569-$0.16N/AN/A3/26/2026Q4 2025ACTUActuate Therapeutics-$0.24-$0.18+$0.06-$0.18N/AN/A3/20/2026Q4 2025MREOMereo BioPharma Group-$0.01-$0.01N/A-$0.05$5.30 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ARKTORocket One Inc. Common StockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.801.80INKTMiNK TherapeuticsN/A1.381.38MREOMereo BioPharma GroupN/A6.486.48RKTORocket One Inc. Common StockN/A3.393.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/AINKTMiNK Therapeutics2.87%MREOMereo BioPharma Group62.83%RKTORocket One Inc. Common Stock7.08%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics57.98%INKTMiNK Therapeutics22.48%MREOMereo BioPharma Group6.50%RKTORocket One Inc. Common Stock6.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1023.93 million10.05 millionN/AINKTMiNK Therapeutics304.98 million3.86 millionNo DataMREOMereo BioPharma Group40159.62 million149.24 millionOptionableRKTORocket One Inc. Common Stock419.13 million17.80 millionNot OptionableRKTO, MREO, INKT, and ACTU HeadlinesRecent News About These CompaniesRocket One Inc.27 minutes ago | cnn.comRocket One Inc. Common Stock (NASDAQ:RKTO) Stock Rating Upgraded by Wall Street ZenMay 30 at 1:12 AM | americanbankingnews.comFrom biotech to orbit: Rocket One's AI and space re-brand sends shares flyingMay 29 at 5:07 AM | msn.comRocket One Rebrands From Hoth, Refocusing on Space ComputingMay 28 at 10:28 PM | theglobeandmail.comRKTO Stock Extends Rally After Landing Its First AI Catalyst – Retail Bulls Are Chasing An AI-Space DreamMay 28 at 10:28 PM | finance.yahoo.comHoth Therapeutics’ pivot to AI in space sees stock rocket after rebrandMay 28 at 10:28 PM | fiercebiotech.comFHoth Therapeutics, Inc.: Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra ...May 27 at 10:52 PM | finanznachrichten.deHoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation ...May 27 at 10:52 PM | tmcnet.comRocket One Rebrand Marks Strategic Shift Toward Space AI Chip and Orbital Computing Markets (RKTO)May 27 at 10:52 PM | finance.yahoo.comHOTH’s Pivot From Biotech To Space Tech Sparks Massive Rally In Stock – Retail Underlines Importance Of Securing Fresh DealsMay 27 at 10:52 PM | finance.yahoo.comHoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense ApplicationsMay 27 at 8:11 AM | prnewswire.comHoth Therapeutics (HOTH) Projected to Post Quarterly Earnings on WednesdayMay 27 at 2:02 AM | americanbankingnews.comHoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology PlatformMay 26, 2026 | prnewswire.comHoth Therapeutics, Inc.: AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of ...May 20, 2026 | finanznachrichten.deHoth Therapeutics shares slide after shift toward AI semiconductor strategy (HOTH)May 20, 2026 | msn.comAI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor ArchitectureMay 19, 2026 | prnewswire.comHoth Therapeutics Launches Rocket One Space Subsidiary InitiativeMay 6, 2026 | tipranks.comHoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer PatientsMay 5, 2026 | prnewswire.comHoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming SemaglutideApril 14, 2026 | prnewswire.comREPL, HOTH, ONCO stocks hit 52-week lows: What's driving the selloff in these biotech plays?April 14, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRKTO, MREO, INKT, and ACTU Company DescriptionsActuate Therapeutics NASDAQ:ACTU$2.02 -0.06 (-2.88%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$2.06 +0.04 (+1.73%) As of 05/29/2026 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.MiNK Therapeutics NASDAQ:INKT$12.20 0.00 (0.00%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$12.20 +0.00 (+0.02%) As of 05/29/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Mereo BioPharma Group NASDAQ:MREO$0.34 0.00 (-0.29%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$0.33 -0.02 (-4.36%) As of 05/29/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Rocket One Inc. Common Stock NASDAQ:RKTO$1.70 +0.34 (+25.00%) As of 05/28/2026Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
